TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04926467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Pre-operative treatment: Nab-paclitaxel (125 mg/m2), gemcitabine (1000 mg/m2), and cisplatin (25 mg/m2) will be given on Day 1 and 8 of a 21-day cycle. Patients will receive anakinra 100 mg injection twice a day starting on day 1 of chemotherapy. Anakinra will be self-administered by the patients and will be discontinued 2 days prior to surgery. Total number of cycles = 4.~Post-operative treatment: 5-Fluorouracil (2400 mg/m2 CI for 48 hours), oxaliplatin (85 mg/m2), and irinotecan (150 mg/m2) will be given once every 2 weeks (1 cycle =14 days). Patients will receive anakinra 100 mg injection subcutaneously twice a day starting on day 1 of chemotherapy (initiated within 4-8 weeks after surgery). Anakinra will be self-administered by the patient throughout the treatment without any break. Total number of cycles = 8.
Study: NCT04776135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Suspension
Study: NCT03278639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation
Description: Training will be directed to ameliorate gait and balance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiology
Description: Training will be directed to ameliorate gait and balance
Study: NCT06716970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR12000 75mg placebo
Description: Matching placebo of QR12000 75mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QR12000 75mg placebo
Description: Matching placebo of QR12000 75mg QD
Study: NCT05690737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi training
Description: The 24-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 33-short form Yang-style Tai Chi Chuan will be adopted. The Tai Chi sessions will be operated by qualified/certified instructors. Each 1-hour training session will consist of 10 minutes brief warm-up stretching session followed by 45 minutes standard Tai Chi routine activities, and 5 minutes of cool-down stretching. The Tai Chi instructors will have to attend a training session that ensure all of them will deliver the same intervention protocol throughout the study. The research assistant will monitor the fidelity of intervention by visiting the Tai Chi sessions frequently. The training activity will be delivered in group. The group size is 25-30 persons. During the 24 weeks follow-up period, the participants are required to practice Tai Chi with the same frequency by themselves.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard prophylactic medication
Description: Participants assigned to the control group will follow the collaborated neurologist's recommendation, to take the prophylactic medication. The Multidisciplinary Panel on Neuropathic Pain (MPNP) of Hong Kong has published the treatment algorithm for migraine, which is in line with the guideline of the Scottish Intercollegiate Guidelines Network (SIGN) on the pharmacological management of migraine (SIGN 155). Beta-blockers, specifically metoprolol and propranolol, are one of the first-line treatments for migraine prophylaxis. The dosage will start on 10mg and slowly increase by 10mg every week until the dosage reached the highest dose of 150mg/day. The whole course will last for 48 weeks. The second line drug such as amitriptyline and the third line drug such as gabapentin will be adopted according to doctor's judgement if necessary. RA will help the participants to make appointment with the neurological doctor, to obtain the prescription. The adverse events will be recorded accordingly.
Study: NCT05691426

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of pulse wave amplitude (PWA)
Description: Assessment of pulse wave amplitude (PWA) through peripheral arterial tonometry (PAT) using the device EndoPAT (Itamar Medical)

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of pulse wave amplitude (PWA)
Description: Assessment of pulse wave amplitude (PWA) through peripheral arterial tonometry (PAT) using the device EndoPAT (Itamar Medical)

Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary Nitric Oxide
Description: assessment the levels of salivary Nitric Oxide using a Nitric Oxide colorimetric detection kit,

Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary Nitric Oxide
Description: assessment the levels of salivary Nitric Oxide using a Nitric Oxide colorimetric detection kit,
Study: NCT04964960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is an immunotherapy that can help fight certain cancers.
Study: NCT05765968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double Stimulation Protocol
Description: cummulative live birth outcome after two cycles of in virto fertilization using double stimulation protocol, which refers to two cycles of ovarian stimulation in both follicular phase and luteal phase within the same menstrual cycle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antagonist Stimulation Protocol
Description: cummulative live birth outcome within no more than two cycles of in virto fertilization using classical antagonist protocol
Study: NCT05735080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-315
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-315
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-315
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-315
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be combined with INX-315
Study: NCT05664997

Intervention type: BEHAVIORAL
Intervention: playing assessment
Description: Investigators used Edinburgh Handedness Inventory, the Wong-Baker Faces Pain Rating Scale, the Disability of Arm, Shoulder and Hand - Sports/Musicians (DASH-SM), the Rapid Upper Limb Assessment, and the 11-item revised version of the Occupational Balance Questionnaire (OBQ11 - T). All have their Turkish validity studies. A correlation analysis was performed to examine the relationship between the variables.
Study: NCT04964960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-paclitaxel is a taxane derivative that is an albumin-bound paclitaxel nanoparticle formulation that promotes microtubule assembly.
Study: NCT05789732

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo treatment once daily.
Study: NCT04964960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is a taxane derivative that promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed is an antifolate agent that disrupts folate-dependent metabolic processes essential for cell replication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is a platinum compound alkylating agent which covalently binds to DNA and interferes with the function of DNA by producing interstrand DNA cross-links.
Study: NCT05789732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: Patients will receive Silodosin 8 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Patients will receive Tadalafil 5 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin and Tadalafil
Description: Patients will receive Silodosin 8mg in combination with Tadalafil 5 mg once daily.
Study: NCT04925622

Intervention type: DIAGNOSTIC_TEST
Intervention: Complex eye movement exam
Description: Subjects will undergo a complex eye exam which will capture fixation, optokinetic nystagmus, guided saccades, microsaccades, smooth pursuit, and pupillometry.~Eye tracking equipment will be set and calibrated to the participant who will then perform the full 10 minute testing protocol with instructions from the investigator. After this, they will take a five minute break. The oculomotor testing protocol will be repeated twice.

Intervention type: DIAGNOSTIC_TEST
Intervention: Complex eye movement exam
Description: Subjects will undergo a complex eye exam which will capture fixation, optokinetic nystagmus, guided saccades, microsaccades, smooth pursuit, and pupillometry.~Eye tracking equipment will be set and calibrated to the participant who will then perform the full 10 minute testing protocol with instructions from the investigator. After this, they will take a five minute break. The oculomotor testing protocol will be repeated twice.

Intervention type: DIAGNOSTIC_TEST
Intervention: Complex eye movement exam
Description: Subjects will undergo a complex eye exam which will capture fixation, optokinetic nystagmus, guided saccades, microsaccades, smooth pursuit, and pupillometry.~Eye tracking equipment will be set and calibrated to the participant who will then perform the full 10 minute testing protocol with instructions from the investigator. After this, they will take a five minute break. The oculomotor testing protocol will be repeated twice.
Study: NCT06567834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tecnis Symfony Optiblue/Tecnis Symfony Optiblue Toric (Models ZXR00V/ZXW150)
Description: Multifocal IOL with violet light filtration and high-resolution lathing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis Symfony/Tecnis Symfony Toric (Models ZXR00/ZXT150)
Description: Multifocal IOL with ultraviolet filtration
Study: NCT04220723

Intervention type: OTHER
Intervention: Frailty Assessment
Description: Liver Frailty Index measurements:~1. Grip strength: the average of three trials, measured in the subject's dominant hand using a hand dynamometer~2. Timed chair stands: measured as the number of seconds it takes to do five chair stands with the subject's arms folded across the chest~3. Balance testing: measured as the number of seconds that the subject can balance in three positions (feet placed side-to-side, semitandem, and tandem) for a maximum of 10 seconds each.

Intervention type: OTHER
Intervention: Functional Capacity Assessment
Description: Shuttle Walk Test: The patient is required to walk around two cones set 9 metres apart (so the final track is 10 metres) in time to a set of auditory beeps played on a CD. Initially, the walking speed is very slow, but each minute the required walking speed progressively increases. The patient walks for as long as they can until they are either too breathless or can no longer keep up with the beeps, at which time the test ends. The number of shuttles is recorded. Each shuttle represents a distance of ten metres (i.e each time the patient reaches a cone is 1 shuttle).
Study: NCT06362369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alintegimod
Description: Alintegimod will be provided in bottles of 30 softgel capsules for oral administration
Study: NCT05439850

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic rotator cuff repair
Description: This procedure is the standard of care for rotator cuff tears who fail conservative treatment options.
Study: NCT06362369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab (Yervoy) will be administered via IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (Opdivo) will be administered via IV
Study: NCT05560230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: A single dose of intraoperatively administered intravenous clonidine 150 μg will be infused over 5-10 min., immediately after intubation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: A single dose of administered intravenous isotonic saline will be infused over 5-10 min., immediately after intubation
Study: NCT04969991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varespladib
Description: 250 mg immediate-release oblong, white, film-coated tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varespladib
Description: 250 mg immediate-release oblong, white, film-coated tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varespladib
Description: 250 mg immediate-release oblong, white, film-coated tablet for oral administration
Study: NCT05439850

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic rotator cuff repair
Description: This procedure is the standard of care for rotator cuff tears who fail conservative treatment options.
Study: NCT04969991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varespladib
Description: 250 mg immediate-release oblong, white, film-coated tablet for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral formulation matched to the oral varespladib tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral formulation matched to the oral varespladib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral formulation matched to the oral varespladib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral formulation matched to the oral varespladib tablet
Study: NCT05439850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bioinductive implant
Description: A bioinductive implant that is designed to promote healing of the torn rotator cuff tendon after surgery.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Imaging
Description: An ultrasound will be performed on each patient one year postoperatively.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: An ultrasound will be performed on each patient one year postoperatively.
Study: NCT04835402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400mg every 6 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation
Description: Percutaneous ablation of one liver metastasis
Study: NCT05836610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: intravenous bolus hydrocortisone therapy during hypothermia treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: intravenous bolus hydrocortisone therapy during hypothermia treatment
Study: NCT05935930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 10 MG/ML Injection
Description: Propofol infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane Inhalation Liquid
Description: Sevoflurane inhalation
Study: NCT06509542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Objective assessment of upper limb use during activities in ecological situation
Description: Twenty-five patients will be recorded performing three activities during their rehabilitation: getting dressed, preparing a meal, and eating a meal. The movements of their upper limbs will be tracked using wrist-worn accelerometers and video cameras.
Study: NCT03994991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active TMS
Description: Transcranial magnetic stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham TMS
Description: Sham transcranial magnetic stimulation
Study: NCT05987527

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine sample
Description: Routine procedures

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine sample
Description: Routine procedures
Study: NCT06262360

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia with mask ventilation
Description: Randomization to General anesthesia with mask ventilation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia and spontaneous laryngeal mask ventilation
Description: Randomization to General anesthesia and spontaneous laryngeal mask ventilation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia with spontaneous laryngeal mask ventilation with pressure support
Description: Randomization to General anesthesia with spontaneous laryngeal mask ventilation with pressure support
Study: NCT05987527

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Routine procedures

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Routine procedures

Intervention type: OTHER
Intervention: Lifestyle questionnaire
Description: Lifestyle questionnaire

Intervention type: OTHER
Intervention: Lifestyle questionnaire
Description: Lifestyle questionnaire
Study: NCT04265209

Intervention type: DRUG
Group type: OTHER
Intervention: SPECT
Description: \[123I\]-FP-CIT SPECT imaging procedure

Intervention type: DRUG
Group type: OTHER
Intervention: SPECT
Description: \[123I\]-FP-CIT SPECT imaging procedure

Intervention type: DRUG
Group type: OTHER
Intervention: PET
Description: \[18F\] LBT-999 PET imaging procedure

Intervention type: DRUG
Group type: OTHER
Intervention: PET
Description: \[18F\] LBT-999 PET imaging procedure
Study: NCT04729634

Intervention type: OTHER
Group type: OTHER
Intervention: Mobilization
Description: Mobilization and breathing exercises according to clinical care
Study: NCT05676164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KANG XIAN
Description: This product is a liquid composed of silica, stabilizer, xylitol, flavoring agent and water. The pH value of the product is 5.0 \~ 8.0, and the total heavy metal content (measured by Pb2+) is less than 10µg/ml.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TIAN XIA
Description: The products are dark yellow granules made from rice, soybean, lotus root powder, orange peel, coix seed and yam.
Study: NCT05879146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Given by PO
Study: NCT05380661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-catheterization
Description: Participants will perform self-catheterization, following the same routine for intermittent catheterization at home

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-catheterization
Description: Participants will perform self-catheterization, following the same routine for intermittent catheterization at home

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheterization performed by urology nurse, participant blinded to time of procedure
Description: Participant will undergo procedure to completely empty bladder; Participant in supine position, and resting blood pressure and heart rate will be recorded for period of 5 minutes prior to catheterization; Perineum and genital areas will be draped and they will be not aware about exact timing of catheterization Catheterization will be conducted following standard clinic procedure by experience urology nurse.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheterization performed by urology nurse, participant blinded to time of procedure
Description: Participant will undergo procedure to completely empty bladder; Participant in supine position, and resting blood pressure and heart rate will be recorded for period of 5 minutes prior to catheterization; Perineum and genital areas will be draped and they will be not aware about exact timing of catheterization Catheterization will be conducted following standard clinic procedure by experience urology nurse.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheterization performed by urology nurse, participant aware of time of procedure
Description: Participant will undergo procedure to completely empty bladder; Participant in supine position, and resting BP and HR will be recorded for period of 5 minutes prior to catheterization; Perineum and genital areas will be visible to participant and they will be fully aware about exact timing of catheterization Catheterization will be conducted following standard clinic procedure by experience urology nurse.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheterization performed by urology nurse, participant aware of time of procedure
Description: Participant will undergo procedure to completely empty bladder; Participant in supine position, and resting BP and HR will be recorded for period of 5 minutes prior to catheterization; Perineum and genital areas will be visible to participant and they will be fully aware about exact timing of catheterization Catheterization will be conducted following standard clinic procedure by experience urology nurse.
Study: NCT06032286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skinstylus microneedling device
Description: Microneedling, also known as percutaneous collagen induction (PCI), is a minimally invasive technique where small needles create microscopic wounds in the skin inducing collagen formation.
Study: NCT05246605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: change in body position
Description: changing from supine to prone position and the back to supine
Study: NCT06015698

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic tubal disconnection
Description: 1. The tube is grasped in the isthmic portion of the tube at least 2cm from the cornua. Bipolar coagulation will provide a more localized area of tubal burn so requiring at least 3cm of the tube to be coagulated~2. The electrosurgical generator should set to deliver a power of 25W in nonmodulated mode to desiccate tissue sufficiently~3. The tube should be coagulated with 2 to 3 contiguous burns to provide an area of about 3cm of coagulation. Th endpoint of coagulation is cessation of the current flow~4. Then, the tube is severed in the middle of the burn area with laparoscopic scissors~5. Ensure adequate hemostasis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic salpingectomy
Description: 1. The tube will be removed from its anatomical attachements by progressive bipolar coagulation~2. Progressive coagulation and cutting of the mesosalpinx begins at the proximal isthmus of the tube and progresses to the fimbriated end using bipolar coagulation and laparoscopic scissors~3. Removal of the tube through one of the ancillary ports using artery forceps~4. Ensure adequate hemostasis